Pelletizer is Designed for Die-Face Cutting of Hot-Melt Extruded Drugs
The Leistritz LHLG series air-quench pelletizer mates with an extruder and enables die-face cutting of pellets in air for water-soluble pharmaceutical formulations.
The Leistritz LHLG pelletizer on the ZSE-18 twin-screw extruder. Image courtesy of Leistritz.
The Leistritz LHLG series air quench pelletizer mates with an extruder and enables die-face cutting of pellets in air for water-soluble, highly filled, and foamed formulations that are typically used for pharmaceutical and nutraceutical products. The die is electrically heated, and the flow geometry is matched with the formulation and throughput rate. The die, blades, and all contact areas are fabricated of hardened stainless, tool, and carbide steels. Standard features include:
- Electrically heated pelletizing die
- Self-aligning cutter hub with replaceable blades driven by AC motor
- Manually adjusted blades for allowable wear
- Stainless-steel cutting chamber with sight glass and safety interlock
- Height-adjustable support cart on tracks
- Optional, chamber-misting attachments for sticky formulations.
A blower facilitates initial cooling and transport to a secondary cooling and transport mechanism, such as high-velocity venturi blowers, vacuum systems, cyclones, and vibratory cooling/classification equipment. GMP-class systems are available for medical and pharmaceutical environments.
Leistritz has installed LHLG pelletizers in its New Jersey process laboratory to test formulations for use with its ZSE-18, ZSE-27, and ZSE-50 MAXX model twin-screw extruders.
Source: Leistritz
Market Demands and Emerging Technologies Shape Outsourcing Models
June 5th 2025Trends in certain forms of drug delivery, as well as the emergence of artificial intelligence, are playing roles in evolving the nature of partnerships, but there are new types of partnerships gaining steam as well.
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
The Role of On-Demand Manufacturing and Derisking in Accelerating Early Clinical Trial Success
June 4th 2025Small pharmaceutical companies are constantly seeking innovative solutions to streamline early clinical trials. Adaptive clinical trials offer important benefits to sponsors and patients, both from a commercial and ethical standpoint. These trials offer flexibility and efficiency, especially in the early stages, where trial protocols can be adjusted based on interim data, such as introducing new doses or modifying participant sample size. However, adjusting manufacturing demand during an adaptive trial can be complicated, and strict regulatory requirements present significant challenges. On-demand manufacturing provides a robust solution, allowing for real-time supply and demand adjustments and improved trial flexibility. This paper explores how on-demand manufacturing meets the operational needs of adaptive trials and aligns with regulatory expectations.
